Tirzepatide (The Dual Agonist): This is a "next-generation" medication that mimics two hormones: GLP-1 and GIP (Glucose-dependent Insulinotropic Polypeptide)
Steven Heymsfield of Pennington Biomedical Research Center describes the results of the BELIEVE study, which showed that the therapy combination addressed lean mass loss associated with GLP-1-based therapies
Companies emphasize the use of digital platforms, mobile health tools, and telemedicine to facilitate remote patient monitoring and data collection, reducing the need for physical site visits
White patients are more likely to use online weight-loss clinics, while Black and Hispanic patients more often rely on in-person care, particularly primary care physicians
Tirzepatide has also demonstrated impressive weight loss results in clinical trials
These products maintain potency reliably within their stated shelf life, so timing your injections does not require worrying about whether the medication has degraded